黄芪注射液治疗阿霉素致乳腺癌心肌损害的临床观察

目的:观察黄芪注射液对阿霉素所致乳腺癌患者相关性心脏毒性损伤的干预治疗作用。方法:将80例III期乳腺癌患者随机分为治疗组(黄芪加化疗)和对照组(单纯化疗)。两组均给予CAF方案化疗6周期,比较两组化疗前后动态心电图(H0lter)、心脏超声、心肌酶谱的变化情况。结果:化疗后治疗组动态心电图异常发生率为39.2%,明显低于对照组的94.3%,两组间比较,心肌酶谱有统计学意义(P<0.05),心脏超声左心室舒张末内径(LVDd)、舒张早期与晚期充盈速度比值(E/A)、左室射血分数(LVEF)等各项指标的改变差异均有统计学意义(P<0.05)。结论:黄芪是预防和减轻阿霉素引起的急性心脏毒性的有效药物。

Effects of Astragalus injecton on doxorubicin-associated cardiotoxicity in patients with breast cancer

Objective: To study the effects of Astragalus injection on doxorubicin-associated cardiotoxicity in patients with breast cancer(BC).Methods:Eighty BC patients in Stage III were randomly assigned to two groups,the control group was treated with chemotherapy,by using 6 cycles of CAF protocol alone and the treated group with the same chemotherapy and Astragalus injection..The changes in Holter,myocardial enzyme spectrum(MES) and ultrasono-cardiogram(UCG) before and after treatment were observed.Results:After treatment,the incidence of abnormal Holter was lower in the treated group than that in the control group(39.2% vs 94.3%),with a significant differences between the two groups in the parameters of MES(P<0.05);UCG showed a significant difference between the two groups in the left ventricular diastolic diameter(LVDd)),the ratio of early and late diastolic transmitral peak flow velocity(E/A),and the theleft ventricular ejection fraction(LVEF).Conclusion:Astragalus injection is an ideal drug for preventing and reducing the acute doxorbincin-induced cardiotoxicity.